

## 2024 Current Fiscal Year Report: Disease, Disability, and Injury Prevention and Control Special Emphasis Panel

Report Run Date: 04/18/2024 10:52:57 PM

<b>1. Department or Agency</b>		<b>2. Fiscal Year</b>	
Department of Health and Human Services		2024	
<b>3. Committee or Subcommittee</b>		<b>3b. GSA Committee No.</b>	
Disease, Disability, and Injury Prevention and Control Special Emphasis Panel		1910	
<b>4. Is this New Fiscal Year?</b>	<b>5. Current Charter</b>	<b>6. Expected Renewal Date</b>	<b>7. Expected Term Date</b>
No	09/18/2022	09/18/2024	
<b>8a. Was Terminated During Fiscal Year?</b>	<b>8b. Specific Termination Authority</b>		<b>8c. Actual Term Date</b>
No			
<b>9. Agency Recommendation for Next Fiscal Year</b>	<b>10a. Legislation Req to Terminate?</b>	<b>10b. Legislation Pending?</b>	
Continue	Not Applicable	Not Applicable	
<b>11. Establishment Authority</b> Authorized by Law			
<b>12. Specific Establishment Authority</b>	<b>13. Effective Date</b>	<b>14. Committee Type</b>	<b>14c. Presidential?</b>
42 USC 217a	11/17/1962	Continuing	No
<b>15. Description of Committee</b> Grant Review Committee			
<b>16a. Total Number of Reports</b>	No Reports for this Fiscal Year		
<b>17a. Open</b>	<b>17b. Closed</b>	<b>17c. Partially Closed</b>	<b>Other Activities</b>
0	0	0	0
<b>17d. Total</b>			
0			
<b>Meetings and Dates</b>			
No Meetings			

	Current FY	Next FY
<b>18a(1). Personnel Pmts to Non-Federal Members</b>	\$0.00	\$0.00
<b>18a(2). Personnel Pmts to Federal Members</b>	\$0.00	\$0.00
<b>18a(3). Personnel Pmts to Federal Staff</b>	\$0.00	\$0.00
<b>18a(4). Personnel Pmts to Non-Member Consultants</b>	\$0.00	\$0.00
<b>18b(1). Travel and Per Diem to Non-Federal Members</b>	\$0.00	\$0.00
<b>18b(2). Travel and Per Diem to Federal Members</b>	\$0.00	\$0.00
<b>18b(3). Travel and Per Diem to Federal Staff</b>	\$0.00	\$0.00
<b>18b(4). Travel and Per Diem to Non-member Consultants</b>	\$0.00	\$0.00
<b>18c. Other(rents,user charges, graphics, printing, mail, etc.)</b>	\$0.00	\$0.00
<b>18d. Total</b>	\$0.00	\$0.00
<b>19. Federal Staff Support Years (FTE)</b>	0.00	0.00

**20a. How does the Committee accomplish its purpose?**

During Fiscal Year (FY) 2023, the Disease, Disability, and Injury Prevention and Control Special Emphasis Panel reviewed 326 applications for grant, contract solicitation and cooperative agreement assistance to fund a broad range of research and to develop programs. Of the 326 grant, contract and cooperative agreement applications, 109 applications were recommended and approved for funding for a total \$91,875,018.

**20b. How does the Committee balance its**

**membership?**

The Disease, Disability, and Injury Prevention and Control Special Emphasis Panel membership represented expertise pertinent to the respective subject areas of each Special Emphasis Panel and included representation from all areas of the public, and academia. Membership was balanced in terms of geographic, demographic, and points of view represented.

**20c. How frequent and relevant are the Committee Meetings?**

Meetings are held as necessary to review applications and proposals for research projects, grants, and cooperative agreements. During FY 2023, the Special Emphasis Panels met 38 times. This reflects the continuing critical role of the Disease, Disability, and Injury Prevention and Control Special Emphasis Panel in CDC's grant and cooperative agreement review process.

**20d. Why can't the advice or information this committee provides be obtained elsewhere?**

One of the most important methods CDC utilizes to accomplish its mission is through awarding grants. The Disease, Disability, and Injury Prevention and Control Special Emphasis Panel provides comprehensive and reliable evaluations of application reviews and proposals for research projects, grants and cooperative agreements in the areas of the causes, prevention and control of diseases, disabilities, injuries and impairments of public health significance; exposure to hazardous substances in the environment; health promotion and education; and other related activities that promote health and well-being. Reviews are conducted under the highest ethical standards by including federal and private subject matter experts representing diverse populations and

interests assuring that the selection of applications meet program requirements with established criteria and best practices. The integrity of the review process, the ability to award and process grants that are credible, equitable, timely and unbiased and CDC's responsiveness to applicants is facilitated by the panel.

**20e. Why is it necessary to close and/or partially closed committee meetings?**

All Special Emphasis Panel meetings were closed in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. The review and discussion of the applications could reveal confidential trade secrets or commercial property such as patentable material and information of a confidential nature, including personal information concerning individuals associated with the applications, the disclosure of which would constitute an unwarranted invasion of personal privacy.

**21. Remarks**

The Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP) is a grant review committee and does not generate reports. The members of this Special Emphasis Panel (SEP) do not have standing appointments and serve on an as needed basis for meetings throughout the fiscal year. Therefore, the Members list reflects meeting dates, not appointment start and end dates. While only one meeting date is listed as an appointment start and end date, a member may have attended several meetings, either as a chairperson, co-chair, or as a member, throughout the fiscal year. As a result, the Members list, including the number of chairs, may not align or directly match to specific meeting dates. Meeting rosters, including members'

affiliations and zip codes are available online at  
<https://www.cdc.gov/faca/committees/ddipcsep/index.html>.

Members generally serve for 1-day meetings and some members are appointed to the SEP multiple times for multiple meetings. The following members were appointed and served on the SEP multiple times for multiple meetings: Antoine Alston (3/7/2023; 5/17/2023); Gaylene Armstrong (4/17/2023; 5/17/2023); Ann Backus (11/15/2022; 5/17/2023); Casper Bendixsen (2/21/2023; 5/17/2023); Andrew Bowman (4/11/2023; 4/13/2023); C. Perry Brown (3/19/2023; 4/21/2023); Vanessa Casanova (11/15/2022; 5/17/2023); Sang Choi (11/15/2022; 2/23/2023; 5/17/2023); Gheorghe Doros (4/11/2023; 4/12/2023); Christopher Eckhardt (2/7/2023; 5/17-18/2023); David Gilkey (2/21-22/2023; 2/23-24/2024); Vijay Golla (2/21-22/2023; 2/23-24/2023); Aubree Gordon 4/12/2023; 4/13/2023); Karen Heaton 2/22-23/2023; 2/23-24/2023); Salah Issa 11/15/2022; 5/17/2023); Xu Ji (4/21/2023; 8/28-31/2023); Deborah Johnson-Shelton (4/19/2023; 8/28-31/2023); Russell Kirby (4/11/2023; 4/13/2023; 8/28-31/2023); Hang Lee (4/11/2023; 4/12/2023; 4/13/2023); Soo-Jeong 2/21-22/2023; 3/22/2023); Guohu Li (2/23-24/2023; 8/28-31/2023); Gilbert Liu 3/29/2023; 8/28-31/2023); Ephraim Massawe (3/22/2023; 5/17/2023); Imelda Moise (4/11/2023; 4/12/2023); Justin Moore (4/19/2023; 8/28-31/2023); Gwendolyn Morris (4/19/2023; 4/21/2023); Frances Otuonye (2/21-22/2023; 5/25/2023); Corliss Outley (3/28/2023; 5/17-18/2023); Mark Pereira (4/19/2023; 8/28-31/2023); Tobili Sam-Yellowe (4/11/2023; 4/13/2023); Diana Schwerha (2/21-22/2023; 6/8/2023); Grace Sembajwe (12/6/2022; 6/8/2023); Shankar Viswanathan (4/12/2023; 5/16-17/2023); Jun Wang (2/21-22/2023;

2/23-24/2023); Richard Webby (4/11/2023; 4/12/2023; 4/13/2023); and Donglan Zhang (4/19/2023; 4/21/2023). There were 38 SEP meetings held and 54 Chairs and co-Chairs served on the panel review meetings. GSA Comment: The agency did not complete the FY23 ACR for this committee.

### **Designated Federal Officer**

Gladys G. Lewellen Director, FACAP and  
Committee Management Officer, CDC

### **Narrative Description**

The Disease, Disability, and Injury Prevention and Control Special Emphasis Panel shall review applications and proposals for research projects, grants, and cooperative agreements in order to provide advice and guidance to the Secretary, HHS; the Director, Centers for Disease Control and Prevention (CDC), and Administrator, Agency for Toxic Substances and Disease Registry (ATSDR), regarding the concept review, scientific and technical merit of grant and cooperative agreement assistance applications, and contract proposals relating to the causes, prevention, and control of diseases, disabilities, injuries, and impairments of public health significance; exposure to hazardous substances in the environment; health promotion and education; and other related activities that promote health and well-being.

### **What are the most significant program outcomes associated with this committee?**

Checked if  
Applies

Improvements to health or safety	<input checked="" type="checkbox"/>
Trust in government	<input checked="" type="checkbox"/>
Major policy changes	<input type="checkbox"/>
Advance in scientific research	<input checked="" type="checkbox"/>
Effective grant making	<input checked="" type="checkbox"/>
Improved service delivery	<input type="checkbox"/>

- |                                                   |                                     |
|---------------------------------------------------|-------------------------------------|
| Increased customer satisfaction                   | <input checked="" type="checkbox"/> |
| Implementation of laws or regulatory requirements | <input type="checkbox"/>            |
| Other                                             | <input type="checkbox"/>            |

**Outcome Comments**

N/A

**What are the cost savings associated with this committee?**

Checked if Applies

- |                            |                                     |
|----------------------------|-------------------------------------|
| None                       | <input type="checkbox"/>            |
| Unable to Determine        | <input checked="" type="checkbox"/> |
| Under \$100,000            | <input type="checkbox"/>            |
| \$100,000 - \$500,000      | <input type="checkbox"/>            |
| \$500,001 - \$1,000,000    | <input type="checkbox"/>            |
| \$1,000,001 - \$5,000,000  | <input type="checkbox"/>            |
| \$5,000,001 - \$10,000,000 | <input type="checkbox"/>            |
| Over \$10,000,000          | <input type="checkbox"/>            |
| Cost Savings Other         | <input type="checkbox"/>            |

**Cost Savings Comments**

N/A

**What is the approximate Number of recommendations produced by this committee for the life of the committee?**

0

**Number of Recommendations Comments**

The Disease, Disability, and Injury Prevention and Control Special Emphasis Panel is a grant application review committee and does not make recommendations.

**What is the approximate Percentage of these recommendations that have been or will be Fully implemented by the agency?**

0%

**% of Recommendations Fully Implemented Comments**

The Disease, Disability, and Injury Prevention and Control Special Emphasis Panel is a grant application review committee and does not make recommendations.

**What is the approximate Percentage of these recommendations that have been or will be Partially implemented by the agency?**

0%

**% of Recommendations Partially Implemented Comments**

The Disease, Disability, and Injury Prevention and Control Special Emphasis Panel is a grant application review committee and does not make recommendations.

**Does the agency provide the committee with feedback regarding actions taken to implement recommendations or advice offered?**

Yes ☐ No ☐ Not Applicable ☒

**Agency Feedback Comments**

The Disease, Disability, and Injury Prevention and Control Special Emphasis Panel is a grant application review committee and does not make recommendations. The agency provides the committee and the public information on award funding.

**What other actions has the agency taken as a result of the committee's advice or recommendation?**

Checked if Applies

Reorganized Priorities	<input type="checkbox"/>
Reallocated resources	<input type="checkbox"/>
Issued new regulation	<input type="checkbox"/>
Proposed legislation	<input type="checkbox"/>
Approved grants or other payments	<input checked="" type="checkbox"/>
Other	<input type="checkbox"/>

**Action Comments**

N/A

**Is the Committee engaged in the review of applications for grants?**

Yes

What is the estimated Number of grants reviewed for approval 326

What is the estimated Number of grants recommended for approval 109

What is the estimated Dollar Value of grants recommended for approval \$93,120,688

**Grant Review Comments**



During fiscal year 2022, the Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP) Funding Opportunity Announcement (FOA) SEP SIP22-007 (convened on May 11, 2022) was approved for funding of which one (1) application was awarded \$245,670 in funding during fiscal year 2023. Also, SEP IP22-001 (convened on June 29-30, 2022) was approved for funding and one (1) application was awarded \$1,000,000 during fiscal year 2023 for a total dollar value of grants recommended in FY23 of \$93,120,688. In addition, SEP CE24-001, Panel A convened on March 16-17, 2023, and ten (10) applications were reviewed and \$42,364,734 was requested but unfunded/approved at this time and SEP CE24-001, Panel B convened on March 17-18, 2023, and eight (8) cooperative agreements were reviewed and \$33,660,000 was requested but unfunded/approved at this time. Additionally, SEP IP23-006 & IP23-007 convened on March 7, 2023, and ten (10) cooperative agreements were reviewed and \$10,215,502 was requested and five (5) approved, however, four (4) was unfunded during fiscal year 2023. Also, IP23-002 and IP23-003 convened on March 29, 2023, and eight (8) cooperative agreements were reviewed and \$9,907,838 was requested and three (3) approved, however, two (2) was unfunded during fiscal year 2023. IP23-001, -004, -005 convened on April 11, 2023, and six (6) cooperative agreements were reviewed and \$6772585.71 was requested and two (2) were approved but unfunded during fiscal year and one (1) will not be funded. PS23-001 and PS23-005 convened on May 24, 2023, and nine (9) cooperative agreements were reviewed and \$23,968,704 was requested and four (4) were approved however, three (3) were not funded during fiscal year 2023. Also, DP23-001, Panel B convened on April 19-20, 2023, and twelve (12) applications were reviewed and \$22,839,128 was requested but unfunded/approved at this time and DP24-004 convened on August 28-31, 2023, and thirty-nine (39) applications were reviewed and \$194,936,446.51 was requested but unfunded/approved at this time. Finally, PAR18-812 convened on February 9, 2023, and three (3) applications were reviewed and \$4,193,171 was requested but unfunded/approved at this time and PAR18-812 #2 convened on June 8, 2023, and one (1) application was reviewed and \$1,898,190 was requested but unfunded/approved at this time.

#### **How is access provided to the information for the Committee's documentation?**

Checked if Applies

Contact DFO	<input checked="" type="checkbox"/>
Online Agency Web Site	<input checked="" type="checkbox"/>
Online Committee Web Site	<input checked="" type="checkbox"/>
Online GSA FACA Web Site	<input checked="" type="checkbox"/>
Publications	<input type="checkbox"/>
Other	<input type="checkbox"/>

**Access Comments**

<https://www.cdc.gov/faca/committees/ddipcsep/index.html>